Table 1.
Prevalence of multimorbidity by gender, cancer type and according to age group at cancer diagnosis in 261,745 cancer patients diagnosed in the period 2005–2015, Denmark.
| Age <55 years at cancer diagnosis | Age 55–69 years at cancer diagnosis | Age ≥ 70 years at cancer diagnosis | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Comorbidity | ≥2 comorbidities | Number | Comorbidity | ≥2 comorbidities | Number | Comorbidity | ≥2 comorbidities | ||||||||||
| N | % | Median | IQR | % | 95% CI | N | % | Median | IQR | % | 95% CI | N | % | Median | IQR | % | 95% CI | |
| Total | 42,139 | 0 | 0–1 | 9 | 9–10 | 106,606 | 1 | 0–1 | 22 | 22–23 | 113,000 | 1 | 0–2 | 39 | 38–39 | |||
| Sex | ||||||||||||||||||
| Male | 12,799 | 30 | 0 | 0–1 | 11 | 10–11 | 55,381 | 52 | 1 | 0–1 | 23 | 22–23 | 61,162 | 54 | 1 | 0–2 | 38 | 37–38 |
| Female | 29,340 | 70 | 0 | 0–1 | 9 | 8–9 | 51,225 | 48 | 0 | 0–1 | 22 | 21–22 | 51,838 | 46 | 1 | 0–2 | 40 | 40–41 |
| Cancer site | ||||||||||||||||||
| Breast | 13,260 | 31 | 0 | 0–1 | 7 | 7–8 | 20,728 | 19 | 0 | 0–1 | 18 | 17–18 | 13,274 | 12 | 1 | 0–2 | 36 | 35–37 |
| Lung | 3517 | 8 | 0 | 0–1 | 20 | 19–21 | 16,690 | 16 | 1 | 0–2 | 36 | 35–36 | 19,608 | 17 | 2 | 1–3 | 51 | 50–52 |
| Prostate | 1392 | 3 | 0 | 0–1 | 8 | 7–10 | 19,680 | 18 | 0 | 0–1 | 16 | 15–16 | 21,238 | 19 | 1 | 0–2 | 29 | 29–30 |
| Colon | 2362 | 6 | 0 | 0–1 | 10 | 9–11 | 9174 | 9 | 0 | 0–1 | 21 | 20–22 | 15,489 | 14 | 1 | 0–2 | 40 | 39–40 |
| Rectum | 1675 | 4 | 0 | 0–1 | 8 | 7–9 | 6025 | 6 | 0 | 0–1 | 17 | 16–18 | 6917 | 6 | 1 | 0–2 | 33 | 32–34 |
| Oesophagus | 453 | 1 | 0 | 0–1 | 16 | 12–19 | 1944 | 2 | 1 | 0–2 | 29 | 27–31 | 1866 | 2 | 1 | 0–2 | 43 | 41–45 |
| Stomach | 688 | 1 | 0 | 0–1 | 13 | 10–15 | 2023 | 2 | 1 | 0–2 | 28 | 26–30 | 2467 | 2 | 1 | 0–2 | 43 | 41–45 |
| Oropharynx | 237 | 1 | 1 | 0–1 | 24 | 19–30 | 568 | 1 | 1 | 0–2 | 27 | 23–31 | 168 | 0.1 | 1 | 0–2 | 39 | 32–47 |
| Liver | 353 | 1 | 1 | 0–2 | 35 | 31–41 | 1455 | 1 | 2 | 1–3 | 56 | 54–59 | 1502 | 1 | 2 | 1–3 | 56 | 54–59 |
| Pancreas | 790 | 2 | 0 | 0–1 | 17 | 14–19 | 3444 | 3 | 1 | 0–2 | 31 | 29–32 | 4485 | 4 | 1 | 0–2 | 45 | 43–46 |
| Bladder | 461 | 1 | 0 | 0–1 | 14 | 11–17 | 2750 | 2 | 1 | 0–1 | 23 | 21–24 | 4923 | 4 | 1 | 0–2 | 40 | 39–42 |
| Kidney | 1234 | 3 | 0 | 0–1 | 16 | 14–19 | 2903 | 3 | 1 | 0–2 | 30 | 29–32 | 2415 | 2 | 1 | 0–2 | 45 | 43–47 |
| Uterus | 916 | 2 | 0 | 0–1 | 11 | 10–14 | 3357 | 3 | 0 | 0–1 | 17 | 16–18 | 2880 | 3 | 1 | 0–2 | 34 | 32–36 |
| Cervix | 2393 | 6 | 0 | 0–0 | 6 | 5–7 | 774 | 1 | 0 | 0–1 | 19 | 16–22 | 622 | 1 | 1 | 0–2 | 36 | 32–40 |
| Ovary | 1020 | 3 | 0 | 0–1 | 8 | 7–10 | 2019 | 2 | 0 | 0–1 | 17 | 16–19 | 1957 | 2 | 1 | 0–2 | 33 | 31–35 |
| Malignant melanoma | 7990 | 19 | 0 | 0–0 | 4 | 4–5 | 6049 | 6 | 0 | 0–1 | 14 | 14–15 | 4968 | 4 | 1 | 0–2 | 33 | 31–34 |
| Brain + CNS | 1252 | 3 | 0 | 0–1 | 11 | 10–13 | 1742 | 1 | 1 | 0–1 | 24 | 22–26 | 1367 | 1 | 1 | 0–2 | 39 | 36–42 |
| Non-Hodgkin lymphoma | 555 | 1 | 0 | 0–1 | 13 | 11–16) | 1165 | 1 | 1 | 0–1 | 23 | 21–26 | 1410 | 1 | 1 | 0–2 | 37 | 35–40 |
| Leukaemia | 1,591 | 4 | 0 | 0–1 | 10 | 8–11 | 4116 | 4 | 1 | 0–1 | 22 | 21–24 | 5444 | 5 | 1 | 0–2 | 40 | 39–41 |
CI confidence interval, CNS central nervous system, IQR interquartile range.